title: Clinical efficacy of topical nipradilol and timolol on visual field performance in normal-tension glaucoma: a multicenter, randomized, double-masked comparative study.
abstract: OBJECTIVE
  To compare the effects of topical nipradilol and timolol on the visual field in Japanese normal-tension glaucoma (NTG) patients.
  
  
  METHODS
  We enrolled 146 NTG patients. At baseline, age, intraocular pressure (IOP), and mean deviation (MD) by the Humphrey field analyzer were 47.6 (SD 8.5), 14.2 (1.7) mmHg, and -4.5 (3.0) dB. Seventy-two patients were randomly assigned to the 0.25% nipradilol group and 74 patients to the 0.5% timolol ophthalmic solution group twice daily for the 3-year study period. The Humphrey full-threshold 30-2 visual field test was performed every 6 months. The primary end point was the nonparametric O'Brien summary score (sum of the ranks of six slopes calculated from the average of the total deviation in each cluster) in each patient. The secondary analyses were differences in the MD slope, average of the total deviation in each cluster, the corrected pattern standard deviation (CPSD), and the time course of IOP.
  
  
  RESULTS
  No significant intergroup differences were found in baseline characteristics, or in the parameters of the primary and secondary analyses. In both groups, central superior clusters showed negative slopes and IOP decreased by about 1 mmHg from baseline.
  
  
  CONCLUSIONS
  No significant difference in visual field performance or IOP reduction was seen between the nipradilol and timolol groups.
authors.affiliation: Department of Ophthalmology, University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan. araie-tky@umin.ac.jp.
authors.forename: Makoto
authors.initials: M
authors.lastname: Araie
authors.affiliation: Yotsuya-Shirato Eye Clinic, Shinjuku-ku, Tokyo, Japan.
authors.forename: Shiroaki
authors.initials: S
authors.lastname: Shirato
authors.affiliation: Department of Ophthalmology, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan.
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Yamazaki
authors.affiliation: Akasaka Kitazawa Eye Clinic, Minato-ku, Tokyo, Japan.
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kitazawa
authors.affiliation: Department of Biostatistics, School of Public Health, University of Tokyo, Bunkyo-ku, Tokyo, Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ohashi
mesh_terms: D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D011412:Propanolamines / Q000008:administration & dosage*; D013999:Timolol / Q000008:administration & dosage*; D014065:Tonometry, Ocular; D016896:Treatment Outcome; D058609:Visual Field Tests; D014794:Visual Fields / Q000187:drug effects*
chemical_list: D000319:Adrenergic beta-Antagonists; D009883:Ophthalmic Solutions; D011412:Propanolamines; D013999:Timolol; C036089:nipradilol
references.citation: Ophthalmology. 2001 Feb;108(2):247-53
references.pmid: 11158794
references.citation: Ophthalmology. 2002 Apr;109(4):766-70
references.pmid: 11927438
references.citation: Drug Metab Dispos. 2002 Apr;30(4):421-9
references.pmid: 11901096
references.citation: Biometrics. 1984 Dec;40(4):1079-87
references.pmid: 6534410
references.citation: Surv Ophthalmol. 1994 Jul-Aug;39(1):23-42
references.pmid: 7974188
references.citation: Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30
references.pmid: 12049575
references.citation: Surv Ophthalmol. 1999 Jun;43 Suppl 1:S162-70
references.pmid: 10416759
references.citation: Am J Ophthalmol. 1998 Oct;126(4):498-505
references.pmid: 9780094
references.citation: Invest Ophthalmol Vis Sci. 2004 Nov;45(11):4041-8
references.pmid: 15505054
references.citation: Control Clin Trials. 1988 Dec;9(4):327-44
references.pmid: 3203524
references.citation: Arch Int Pharmacodyn Ther. 1983 Mar;262(1):132-49
references.pmid: 6135395
references.citation: Invest Ophthalmol Vis Sci. 2002 Oct;43(10):3243-50
references.pmid: 12356831
references.citation: J Glaucoma. 1999 Apr;8(2):117-23
references.pmid: 10209728
references.citation: Invest Ophthalmol Vis Sci. 2001 Mar;42(3):688-94
references.pmid: 11222528
references.citation: Br J Ophthalmol. 2000 Mar;84(3):293-9
references.pmid: 10684841
references.citation: Arzneimittelforschung. 2006;56(11):729-34
references.pmid: 17220049
references.citation: Brain Res. 1997 Mar 14;751(1):113-23
references.pmid: 9098574
references.citation: Ophthalmic Res. 2002 Nov-Dec;34(6):331-7
references.pmid: 12483019
references.citation: J Glaucoma. 2001 Apr;10(2):121-8
references.pmid: 11316094
references.citation: Ophthalmology. 2001 Nov;108(11):1943-53
references.pmid: 11713061
references.citation: Brain Res. 2002 Dec 20;958(1):10-9
references.pmid: 12468025
references.citation: Eye (Lond). 2004 Oct;18(10):984-9
references.pmid: 15037889
references.citation: Am J Ophthalmol. 1998 Oct;126(4):487-97
references.pmid: 9780093
references.citation: Am J Ophthalmol. 2000 Oct;130(4):429-40
references.pmid: 11024415
references.citation: J Ocul Pharmacol Ther. 2001 Jun;17(3):235-48
references.pmid: 11436944
references.citation: Ophthalmology. 1982 Mar;89(3):268-79
references.pmid: 7088510
references.citation: Arch Ophthalmol. 1977 Jul;95(7):1173-5
references.pmid: 880074
references.citation: Jpn J Ophthalmol. 2003 Mar-Apr;47(2):199-207
references.pmid: 12738555
references.citation: Brain Res. 2007 May 7;1148:28-37
references.pmid: 17368577
references.citation: Eur J Pharmacol. 2002 Oct 11;452(3):263-8
references.pmid: 12359266
references.citation: Ophthalmology. 2004 Nov;111(11):2117-25
references.pmid: 15522380
references.citation: Graefes Arch Clin Exp Ophthalmol. 1989;227(5):408-12
references.pmid: 2806924
references.citation: Invest Ophthalmol Vis Sci. 1998 Apr;39(5):736-43
references.pmid: 9538880
references.citation: Am J Ophthalmol. 1989 Nov 15;108(5):485-95
references.pmid: 2683792
references.citation: Exp Eye Res. 2005 Apr;80(4):501-7
references.pmid: 15781277
references.citation: J Glaucoma. 2002 Jun;11(3):231-8
references.pmid: 12140401
references.citation: Curr Eye Res. 2002 Feb;24(2):114-22
references.pmid: 12187483
references.citation: Arzneimittelforschung. 2006;56(12):820-5
references.pmid: 17260669
references.citation: Ophthalmology. 1996 Feb;103(2):283-8
references.pmid: 8594515
references.citation: Arch Int Pharmacodyn Ther. 1985 Nov;278(1):61-71
references.pmid: 2869737
references.citation: Arch Ophthalmol. 2002 Oct;120(10):1268-79
references.pmid: 12365904